Literature DB >> 25300649

Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.

Zatollah Asemi1, Fatemeh Foroozanfard2, Teibeh Hashemi2, Fereshteh Bahmani1, Mehri Jamilian3, Ahmad Esmaillzadeh4.   

Abstract

BACKGROUND & AIMS: Few studies have examined the effects of calcium plus vitamin D supplementation on glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome (PCOS). This study was conducted to determine the effects of calcium plus vitamin D supplementation on glucose metabolism and lipid concentrations among overweight and obese vitamin D deficient women with PCOS.
METHODS: This randomized double-blind placebo-controlled clinical trial was conducted among 104 overweight and obese vitamin D deficient women diagnosed with PCOS. Participants were randomly assigned into four groups to receive: 1) 1000 mg/d calcium + vitamin D placebo (n = 26); 2) 50,000 IU/wk vitamin D + calcium placebo (n = 26); 3) 1000 mg calcium/d + 50,000 IU/wk vitamin D (n = 26) and 4) calcium placebo + vitamin D placebo (n = 26) for 8 weeks. Fasting blood samples were taken at baseline and after 8 weeks' intervention to measure glucose metabolism and lipid concentrations.
RESULTS: Calcium-vitamin D co-supplementation resulted in higher levels of serum calcium (P = 0.002) and vitamin D (P < 0.001) compared with other groups. Co-supplementation, compared with other groups, led to decreased serum insulin levels (P = 0.03), homeostasis model of assessment-insulin resistance (HOMA-IR) score (P = 0.04) and a significant rise in quantitative insulin sensitivity check index (QUICKI) (P = 0.001). Furthermore, a significant decrease in serum triglycerides (P = 0.02) and VLDL-cholesterol levels (P = 0.02) was seen following the administration of calcium plus vitamin D supplements compared with the other groups. Co-supplementation with calcium and vitamin D had no significant effects on FPG, total-, LDL-, HDL-, and non-HDL-cholesterol levels.
CONCLUSIONS: In conclusion, calcium plus vitamin D supplementation for eight weeks among vitamin D deficient women with PCOS had beneficial effects on serum insulin levels, HOMA-IR, QUICKI, serum triglycerides and VLDL-cholesterol levels, but it did not affect FPG and other lipid profiles. Clinical registration numberwww.irct.ir: IRCT201309275623N10.
Copyright © 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Calcium; Glucose metabolism; Lipid concentrations; Polycystic ovary syndrome; Supplementation; Vitamin D

Mesh:

Substances:

Year:  2014        PMID: 25300649     DOI: 10.1016/j.clnu.2014.09.015

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  32 in total

1.  Vitamin D Status Relates to Reproductive Outcome in Women With Polycystic Ovary Syndrome: Secondary Analysis of a Multicenter Randomized Controlled Trial.

Authors:  Lubna Pal; Heping Zhang; Joanne Williams; Nanette F Santoro; Michael P Diamond; William D Schlaff; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan Myers; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2016-05-17       Impact factor: 5.958

Review 2.  Vitamin D deficiency and essential hypertension.

Authors:  Songcang Chen; Yingxian Sun; Devendra K Agrawal
Journal:  J Am Soc Hypertens       Date:  2015-08-21

3.  Pharmacological and non-pharmacological strategies for obese women with subfertility.

Authors:  Seyed Abdolvahab Taghavi; Madelon van Wely; Shayesteh Jahanfar; Fatemeh Bazarganipour
Journal:  Cochrane Database Syst Rev       Date:  2021-03-25

Review 4.  Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis.

Authors:  Chunla He; Zhoumeng Lin; Sara Wagner Robb; Amara E Ezeamama
Journal:  Nutrients       Date:  2015-06-08       Impact factor: 5.717

5.  Effects of vitamin D supplementation on metabolic indices and hs-CRP levels in gestational diabetes mellitus patients: a randomized, double-blinded, placebo-controlled clinical trial.

Authors:  Roya Yazdchi; Bahram Pourghassem Gargari; Mohammad Asghari-Jafarabadi; Farnaz Sahhaf
Journal:  Nutr Res Pract       Date:  2016-05-16       Impact factor: 1.926

6.  Associations of Vitamin D with Inter- and Intra-Muscular Adipose Tissue and Insulin Resistance in Women with and without Polycystic Ovary Syndrome.

Authors:  David Scott; Anju Joham; Helena Teede; Melanie Gibson-Helm; Cheryce Harrison; Samantha Cassar; Samantha Hutchison; Peter R Ebeling; Nigel Stepto; Barbora de Courten
Journal:  Nutrients       Date:  2016-11-30       Impact factor: 5.717

7.  Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome.

Authors:  Mehri Jamilian; Fatemeh Foroozanfard; Elham Rahmani; Maesoomeh Talebi; Fereshteh Bahmani; Zatollah Asemi
Journal:  Nutrients       Date:  2017-11-24       Impact factor: 5.717

8.  Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial.

Authors:  David Corley Gibbs; Veronika Fedirko; John A Baron; Elizabeth L Barry; W Dana Flanders; Marjorie L McCullough; Rami Yacoub; Tapasya Raavi; Robin E Rutherford; March E Seabrook; Roberd M Bostick
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-11

Review 9.  Vitamin D and Polycystic Ovary Syndrome: a Narrative Review.

Authors:  Yang Mu; Dan Cheng; Tai-Lang Yin; Jing Yang
Journal:  Reprod Sci       Date:  2020-10-28       Impact factor: 3.060

10.  Calcium-Vitamin D Co-supplementation Affects Metabolic Profiles, but not Pregnancy Outcomes, in Healthy Pregnant Women.

Authors:  Zatollah Asemi; Mansooreh Samimi; Mehrnush Amiri Siavashani; Maryam Mazloomi; Zohreh Tabassi; Maryam Karamali; Mehri Jamilian; Ahmad Esmaillzadeh
Journal:  Int J Prev Med       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.